In a release,
The results of
In an independent editorial,
The results of the Phase 2 trial have garnered the support of the
"We are excited about these results and the enthusiasm of our colleagues," said
The Phase 2 trial enrolled 41 patients with a mean age of 55 years with surgically resectable recurrent high-grade GBM, the deadliest form of brain cancer. Patients underwent surgery to remove greater than or equal to 90 percent of their tumors (also referred to as gross total resection), which were then used to manufacture Prophage G-200 vaccine, a patient-specific heat shock protein based therapeutic vaccine. Eligible patients were treated after surgery with Prophage G-200 vaccine once weekly for four weeks, followed by biweekly injections until vaccine depletion. There were no serious adverse events associated with vaccine administration. For further information about this manuscript: http://neuro- oncology.oxfordjournals.org.
The trial was supported through funding from the
This study represents the largest brain tumor vaccine trial ever funded by the NCI and the largest vaccine study ever conducted with Avastin. The study aims to advance the treatment of GBM, the most common and malignant form of brain cancer.
The ALLIANCE trial is investigating the potential benefits of treatment with a combination of Prophage G-200 vaccine and bevacizumab in a three-arm study of approximately 222 patients with surgically resectable recurrent GBM using a primary endpoint of overall survival. The study will compare efficacy of the Prophage G- 200 vaccine administered with bevacizumab either concomitantly or at progression, versus treatment with bevacizumab alone. This study design is supported in part by previous research indicating a potential synergistic effect between the mechanisms of action of Prophage G-200 vaccine and bevacizumab. For additional information about the ALLIANCE trial visit ClinicalTrials.gov using Identifier NCT01814813.
The incidence rates of primary malignant brain and central nervous system cancers have increased over the last three decades. The
Prophage vaccines are individualized cancer vaccine candidates derived from each patient's own tumor. As a result of its individualized nature, each Prophage vaccine contains the precise signals (antigenic fingerprint) of the patient's particular cancer and allows the body's immune system to target only cells bearing this specific fingerprint. Such high precision in immunological targeting represents a distinctly different method for treating cancer compared to conventional anti-cancer treatments such as chemotherapy or radiation therapy. These therapies cause side effects which are sometimes debilitating.
Prophage vaccines are based on
((Comments on this story may be sent to email@example.com))
In a release,